The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.
 
Ibiayi Dagogo-Jack
No Relationships to Disclose
 
Pablo Martinez
No Relationships to Disclose
 
Beow Y Yeap
No Relationships to Disclose
 
Chiara Ambrogio
No Relationships to Disclose
 
Christine A. Lydon
No Relationships to Disclose
 
Tom Nguyen
No Relationships to Disclose
 
A. John Iafrate
Stock and Other Ownership Interests - Archer
Consulting or Advisory Role - Chugai Pharma; Constellation Pharmaceuticals; Debiopharm Group; Roche
Research Funding - Blueprint Medicines
Patents, Royalties, Other Intellectual Property - ArcherDx exclusive license to AMP technology
 
Jochen K Lennerz
No Relationships to Disclose
 
Bruce E. Johnson
Stock and Other Ownership Interests - KEW
Honoraria - Chugai Pharma
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; KEW; Lilly; Merck; Novartis
Research Funding - Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Toshiba (Inst)
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Novartis; Pfizer; Roche/Genentech
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - Bristol-Myers Squibb